The Life Sciences team advised bluebird bio, Inc. (NASDAQ: BLUE) on its tax-free spin-off of its oncology programs and portfolio into 2seventy bio, Inc. (NASDAQ: TSVT), an independent, publicly-traded company. 2seventy launched with a cell therapy pipeline across a range of hematologic and solid tumors. 2seventy’s portfolio also includes a development and U.S. commercialization partnership with Bristol Myers Squibb for ABECMA, a BCMA-directed CAR T cell immunotherapy for multiple myeloma. bluebird bio will continue its work focused on severe genetic disease, with three near-term opportunities to bring transformative gene therapies to patients and their families in the U.S.
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. The company has industry-leading clinical programs for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, and is advancing research to apply new technologies to these and other diseases.
2seventy bio is an immuno-oncology cell therapy company focused on discovering and developing new therapies that disrupt the cancer treatment landscape. The company is working to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors.
The Goodwin team was led by Michael Bison, Lisa Haddad, Gregg Katz, Yasin Akbari, Alex Apostolopoulos, Dan Karelitz, Chris Denn, and Shannyn Henke.
For more details, read the press release and articles in Endpoints, BioSpace, and The Boston Globe.